Drug:
Reaction: EXPOSURE VIA SKIN CONTACT
20260101 - 20261231
No. 401 - 500
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 401 | 26892564 |
US |
76 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 402 | 26892587 |
US |
2 | |
Product use in unapproved indication, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, APREMILAST, |
||||
| 403 | 26892593 |
US |
66 | 2 |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 404 | 26892655 |
EU |
38 | |
Colitis ulcerative, Inappropriate schedule of product administration, Product leakage, Needle issue, Product physical issue, Exposure via skin contact, Accidental exposure to product, Suspected off label use, |
||||
USTEKINUMAB-STBA, USTEKINUMAB-STBA, |
||||
| 405 | 26892794 |
US |
1 | |
Oropharyngeal pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 406 | 26892824 |
US |
77 | 1 |
Accidental exposure to product, Exposure via skin contact, Incorrect dose administered, |
||||
DUPILUMAB, |
||||
| 407 | 26893058 |
US |
16 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 408 | 26893435 |
US |
19 | 2 |
Off label use, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 409 | 26893630 |
US |
61 | 2 |
Accidental exposure to product, Exposure via skin contact, Device difficult to use, Incorrect dose administered by device, Injection site haemorrhage, Wrong technique in product usage process, |
||||
EVOLOCUMAB, EVOLOCUMAB, EVOLOCUMAB, |
||||
| 410 | 26893820 |
US |
49 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 411 | 26893834 |
US |
73 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 412 | 26894185 |
US |
3 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 413 | 26894191 |
US |
68 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 414 | 26894201 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 415 | 26894217 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 416 | 26894971 |
US |
76 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 417 | 26895110 |
US |
2 | |
Exposure via skin contact, Injection site swelling, Injection site discharge, Product complaint, |
||||
TOCILIZUMAB, CALCIUM, ERGOCALCIFEROL, MAGNESIUM, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE INJECTION, DENOSUMAB, DENOSUMAB, HYDROCORTISONE, HYDROCORTISONE, |
||||
| 418 | 26895364 |
US |
38 | 2 |
Product communication issue, Accidental exposure to product, Drug dose omission by device, Device difficult to use, Exposure via skin contact, |
||||
ERENUMAB-AOOE, |
||||
| 419 | 26895407 |
US |
65 | 2 |
Dermatitis atopic, Swelling, Incorrect dose administered, Product administration issue, Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 420 | 26895417 |
US |
62 | 2 |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 421 | 26895456 |
US |
61 | 2 |
Accidental exposure to product, Exposure via skin contact, Headache, |
||||
ERENUMAB-AOOE, |
||||
| 422 | 26895793 |
US |
77 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 423 | 26895805 |
US |
33 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 424 | 26895813 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 425 | 26896134 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 426 | 26896447 |
US |
82 | 2 |
Pneumonia, Exposure via skin contact, Wrong technique in device usage process, Product dose omission issue, Accidental exposure to product, |
||||
MEPOLIZUMAB, |
||||
| 427 | 26896793 |
US |
56 | 1 |
Injection site pain, Device operational issue, Accidental exposure to product, Exposure via skin contact, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 428 | 26896953 |
US |
54 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 429 | 26886643 |
US |
75 | 2 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, Incorrect dose administered, |
||||
DUPILUMAB, |
||||
| 430 | 26886791 |
US |
13 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 431 | 26886829 |
US |
14 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 432 | 26886887 |
US |
47 | 1 |
Drug dose omission by device, Accidental exposure to product, Exposure via skin contact, Product preparation error, |
||||
EVOLOCUMAB, |
||||
| 433 | 26887064 |
US |
78 | 1 |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 434 | 26887070 |
US |
65 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 435 | 26887086 |
US |
58 | 2 |
Glossodynia, Injection site pain, Injection site swelling, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 436 | 26887203 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 437 | 26887320 |
US |
61 | 1 |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 438 | 26887321 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 439 | 26887454 |
US |
70 | 2 |
Drug dose omission by device, Device difficult to use, Accidental exposure to product, Exposure via skin contact, Intentional product misuse, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 440 | 26887455 |
US |
44 | 1 |
Accidental exposure to product, Skin irritation, Exposure via skin contact, Incorrect disposal of product, Product communication issue, |
||||
EVOLOCUMAB, EVOLOCUMAB, ALIROCUMAB, |
||||
| 441 | 26887542 |
US |
74 | 1 |
Accidental exposure to product, Exposure via skin contact, Product communication issue, Wrong technique in device usage process, |
||||
EVOLOCUMAB, |
||||
| 442 | 26887592 |
US |
2 | |
Exposure via skin contact, Accidental exposure to product, Injection site mass, Incorrect dose administered by device, Wrong technique in product usage process, Injection site bruising, Injection site swelling, Injection site pain, |
||||
EVOLOCUMAB, |
||||
| 443 | 26887657 |
US |
81 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 444 | 26887678 |
US |
11 | 2 |
Product use in unapproved indication, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, ALBUTEROL SULFATE, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, CETIRIZINE HYDROCHLORIDE, |
||||
| 445 | 26887896 |
US |
77 | 2 |
Injection site urticaria, Therapeutic response decreased, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 446 | 26887933 |
4 | 2 | |
Pseudoprecocious puberty, Accidental exposure to product by child, Exposure via skin contact, Epiphyses premature fusion, |
||||
ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, |
||||
| 447 | 26888057 |
3 | 2 | |
Precocious puberty, Accidental exposure to product by child, Exposure via skin contact, Epiphyses premature fusion, |
||||
ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, |
||||
| 448 | 26888100 |
US |
85 | 1 |
Exposure via skin contact, Product complaint, |
||||
MEPOLIZUMAB, |
||||
| 449 | 26888222 |
US |
79 | 2 |
Injection site swelling, Injection site erythema, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 450 | 26888377 |
EU |
58 | 1 |
Hereditary motor and sensory neuropathy, Chronic inflammatory demyelinating polyradiculoneuropathy, Balance disorder, Exposure via skin contact, Accidental exposure to product, Incorrect dose administered by device, |
||||
ADALIMUMAB-ADAZ, ADALIMUMAB-ADAZ, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, METHOTREXATE, METHOTREXATE SODIUM, |
||||
| 451 | 26888381 |
US |
67 | 2 |
Injection site haemorrhage, Drug dose omission by device, Device difficult to use, Accidental exposure to product, Exposure via skin contact, Illness, |
||||
EVOLOCUMAB, |
||||
| 452 | 26888562 |
US |
54 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 453 | 26888581 |
US |
43 | 2 |
Accidental exposure to product, Exposure via skin contact, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 454 | 26888609 |
US |
44 | 1 |
Exposure via skin contact, Accidental exposure to product, |
||||
EVOLOCUMAB, |
||||
| 455 | 26888748 |
US |
31 | 2 |
Exposure via skin contact, Accidental exposure to product, |
||||
MEPOLIZUMAB, |
||||
| 456 | 26888840 |
US |
67 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 457 | 26888916 |
US |
8 | 1 |
Injection site haemorrhage, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 458 | 26888968 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 459 | 26889692 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 460 | 26889729 |
US |
82 | 1 |
Dermatitis allergic, Dermatitis atopic, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 461 | 26889775 |
US |
77 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 462 | 26889788 |
US |
||
Injection site erythema, Injection site swelling, Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 463 | 26890075 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 464 | 26890095 |
US |
76 | 2 |
Insomnia, Nausea, Decreased appetite, Product use in unapproved indication, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 465 | 26890347 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 466 | 26890616 |
US |
56 | 2 |
Accidental exposure to product, Exposure via skin contact, Device use error, |
||||
ERENUMAB-AOOE, |
||||
| 467 | 26890811 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 468 | 26890820 |
US |
18 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 469 | 26890828 |
US |
80 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 470 | 26890846 |
US |
58 | 2 |
Multiple use of single-use product, Exposure via skin contact, Wrong technique in product usage process, |
||||
INSULIN GLARGINE, |
||||
| 471 | 26891107 |
US |
66 | 2 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 472 | 26891629 |
US |
2 | |
Mast cell activation syndrome, Injection site pain, Injection site erythema, Dermatitis atopic, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DIPHENHYDRAMINE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE, CETIRIZINE HCL, CETIRIZINE, CHLORDIAZEPOXIDE HYDROCHLORIDE, DOCUSATE SODIUM, DOCUSATE SODIUM - SENNOSIDES, DICYCLOMINE HYDROCHLORIDE, GALCANEZUMAB-GNLM, EPINEPHRINE, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, FAMOTIDINE, HYDROXYCHLOROQUINE SULFATE, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE ORAL, TENAPANOR HYDROCHLORIDE, GLUTATHIONE, KOJIC ACIDSKIN LIGHTENING, LAMOTRIGINE, MAGNESIUM, METRONIDAZOLE, METRONIDAZOLE TOPICAL, NALTREXONE, RIMEGEPANT SULFATE, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, PIMECROLIMUS, PRAZOSIN HYDROCHLORIDE, QUETIAPINE, MONTELUKAST SODIUM, SULINDAC, ERGOCALCIFEROL, |
||||
| 473 | 26891650 |
US |
59 | 2 |
Cataract operation, Inappropriate schedule of product administration, Product container issue, Product complaint, Liquid product physical issue, Exposure via skin contact, Accidental exposure to product, Prescribed underdose, |
||||
PERFLUOROHEXYLOCTANE, ALBUTEROL SULFATE, ALBUTEROL, RIZATRIPTAN, NYSTATIN, NYSTATIN OINTMENT, NYSTATIN CREAM, SENNOSIDES 8.6 MG TABLETS, SENNOSIDES, SENNA LEAF, SENNA, PREGABALIN, FAMOTIDINE, DIAZEPAM, DIAZEPAM ORAL, DIAZEPAM ORAL SOLUTION (CONCENTRATE), BACLOFEN, NALTREXONE, TIRZEPATIDE, |
||||
| 474 | 26891767 |
US |
73 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 475 | 26881244 |
US |
18 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 476 | 26881271 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 477 | 26881302 |
US |
61 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 478 | 26881543 |
CA |
52 | |
Injection site pain, Device issue, Exposure via skin contact, Accidental exposure to product, Underdose, |
||||
INFLIXIMAB-DYYB, |
||||
| 479 | 26881617 |
US |
59 | 2 |
Injection site haemorrhage, Drug dose omission by device, Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 480 | 26881645 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 481 | 26881654 |
US |
||
Injection site swelling, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 482 | 26881852 |
US |
79 | 2 |
Device difficult to use, Accidental exposure to product, Exposure via skin contact, Ill-defined disorder, Pain, |
||||
EVOLOCUMAB, |
||||
| 483 | 26881877 |
US |
2 | |
Exposure via skin contact, Accidental exposure to product, Inappropriate schedule of product administration, Device difficult to use, |
||||
EVOLOCUMAB, |
||||
| 484 | 26882095 |
US |
51 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 485 | 26882167 |
US |
65 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 486 | 26882175 |
US |
77 | 1 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 487 | 26882178 |
US |
78 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 488 | 26882199 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 489 | 26882259 |
US |
2 | |
Product communication issue, Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, EZETIMIBE, |
||||
| 490 | 26882492 |
US |
9 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 491 | 26882496 |
US |
22 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 492 | 26882727 |
US |
49 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 493 | 26882799 |
US |
68 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 494 | 26882930 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
ERENUMAB-AOOE, |
||||
| 495 | 26883200 |
US |
32 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 496 | 26883686 |
US |
65 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 497 | 26883692 |
US |
67 | 2 |
Accidental exposure to product, Device use error, Drug dose omission by device, Headache, Device difficult to use, Exposure via skin contact, |
||||
ERENUMAB-AOOE, ERENUMAB-AOOE, |
||||
| 498 | 26883737 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 499 | 26883751 |
US |
29 | 1 |
Accidental exposure to product, Exposure via skin contact, Inappropriate schedule of product administration, Incorrect dose administered, |
||||
DUPILUMAB, |
||||
| 500 | 26883814 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
ERENUMAB-AOOE, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30